ArticlePloS one2024
Global perspectives of determinants influencing HPV vaccine introduction and scale-up in low- and middle-income countries.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Determinants of human papillomavirus vaccination uptake in Nigeria: a mixed-methods systematic review.BMC public health · 2026Pooled it
- A framework policy analysis of single-dose HPV vaccination adoption in East Africa: a rapid review.BMC health services research · 2026Pooled it
- Human papillomavirus vaccine uptake and its determinants among women in Africa: an umbrella review.Frontiers in public health · 2025Pooled it
- Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.Human vaccines & immunotherapeutics · 2026Article
- Impact of the COVID-19 Pandemic on HPV Vaccination in Low- and Middle-Income Countries: A Scoping Review.Vaccines · 2026Review
- From campaign to continuity: stakeholders' recommendations for integrating HPV vaccination into Nigeria's healthcare system.BMC health services research · 2026Article
- Article
- Marginalized voices on HPV vaccination in India: exploring knowledge, attitudes, and acceptance.Frontiers in global women's health · 2026Article
- Human papillomavirus (HPV) and HPV vaccine awareness in Indigenous communities in Northwest Territories, Canada.PloS one · 2026Article
- Rumors and fears about the HPV vaccine: Perceptions of adolescent girls in government school in Addis Ababa.Human vaccines & immunotherapeutics · 2025Article
- HPV vaccination coverage, hesitancy, and barriers: Insights from a serial cross-sectional study in Shanghai, China (2019-2024).Human vaccines & immunotherapeutics · 2025Article
- Comparison of plant- and mammalian cell-produced human papillomavirus pseudovirions.Journal of virological methods · 2025Article
- Is the HPV vaccine lottery system equitable under constrained vaccine supply? A cross-sectional study in China.Archives of public health = Archives belges de sante publique · 2025Article
- Revisiting HPV vaccination post-COVID: geopolitical, sociocultural, and ethical disparities in global health.International journal for equity in health · 2025Review
- Review
- Developing Community-Informed Communication Resources to Improve Human Papillomavirus Vaccine Uptake in Tonga.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Review
- High-risk human papillomavirus testing for underscreened populations: cost-effectiveness and affordability in three country settings.BMC public health · 2025Article
- Human papillomavirus vaccine coverage surveys in low- and middle-income countries: current efforts and future considerations for very young adolescents.BMJ global health · 2025Review
- Papillomavirus Vaccination Programs and Knowledge Gaps as Barriers to Implementation: A Systematic Review.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving WHO cervical cancer elimination goals will necessitate efforts to increase HPV vaccine access and coverage in low-and-middle-income countries (LMICs). Although LMICs account for the majority of cervical cancer cases globally, scale-up of HPV vaccine programs and progress toward coverage targets in LMICs has been largely insufficient. Understanding the barriers and facilitators that stakeholders face in the introduction and scale-up of HPV vaccination programs will be pivotal in ensuring that LMICs are equipped to optimize the implementation of HPV vaccination programs. This qualitative study interviewed 13 global stakeholders categorized as either academic partners or global immunization partners to ascertain perspectives regarding factors affecting the introduction and scale-up of HPV vaccination programs in LMICs. Global stakeholders were selected as their perspectives have not been as readily highlighted within the literature despite their key role in HPV vaccination programming. The results of this investigation identified upstream (e.g., financial considerations, vaccine prioritization, global supply, capacity and delivery, and vaccine accessibility, equity, and ethics) and downstream (e.g., vaccine acceptability and hesitancy, communications, advocacy, and social mobilization) determinants that impact program introduction and scale-up and confirmed that strong political commitment and governance are significant in garnering support for HPV vaccines. As LMICs introduce HPV vaccines into their national immunization programs and develop plans for scaling up vaccination efforts, strategic approaches to communications and advocacy will also be needed to successfully meet coverage targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.